HLTT(.299)...Q4 revenue, acquisition, new CEO, uplisting......
I bought some more shares at the sub-25 cent level last week for a possible short-term trade opportunity. Based on the January 6 letter to shareholders, I am anticipating there will be an increase in corporate activity (both operational and investor relations related) during 2023. The acquisition of World Reach Holdings and the appointment of new CEO Jelena Olmstead is expected to be completed on January 27. The website for the wound care business started to come online around the end of December (still in the process of full-development, but the management section is available now).......
Based on the wording in the shareholder letter it appears that 2022 Q4 revenue for the wound care business was at a minimum over $2.3M (compared to $766K in 2022 Q3), and there is an expectation that revenue for that business will continue growing in 2023. The uplisting process to one of the higher exchanges is expected to start after HLTT files its 2022 10-K.
Update on Varian Biopharma (in which HLTT has an ownership position): The deal to bring Varian public via the SPK SPAC was terminated in late December. There could be no connection between the termination announcement and HLTT revealing it plans to uplist its stock, but the timing is somewhat interesting to me. As per the HLTT wound care website, Paul Mann continues to be Chairman of both HLTT and Varian.
Some items of interest from the shareholder letter......
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.